Celltrion Healthcare on Sept. 27 announced its decision to expand sales in the Middle East.
He company has got approval to exclusively supply Remsima, its version of Johnson & Johnson’s Remicade from the third quarter this year.
According to the company, its successful bid was due to its aggressive marketing for expanding its presence in the Mideast. Currently, the drug is also being sold inTunisia, Saudi Arabia, Morocco and Jordan.
“Our recent bid in Algeria shows that the market is very friendly, and we will do our best to further stretch out in the Middle East.” a company official said in a statement.
It added that its breast cancer biosimilar Huzuma is also expanding into the Middle East following Europe and Japan. From the third quarter its started selling Herzuma with a local partner Hikma. This is the first time that the drug has been introduced to the Middle East.
Herzuma is a biosimilar based on Herceptin -- which was originally developed by Swiss pharmaceutical giant Roche.
By Song Seung-hyun (firstname.lastname@example.org)